Several apoptosis-inducing systems, including Fas/Fas ligand and TNF-related apoptosis-inducing ligand (TRAIL) and its receptors, are upregulated in myelodysplastic syndrome (MDS). FLIP (FLICE (FAS-associated death-domain-like IL-1b-converting enzyme)-inhibitory protein)) was identified as an inhibitor of FAS and TRAIL signals. Here, we characterized FLIP Long (FLIP L ) and FLIP Short (FLIP S ) expression in bone marrow mononuclear cells (BMMNCs) and in CD34 þ cells of 29 MDS patients, and in 17 normal volunteers. The expression was correlated with apoptotic indices. In CD34 þ cells, FLIP L levels were higher among normal individuals than in MDS patients (P ¼ 0.04). Among total BMMNC, FLIP L levels also tended to be higher in normal subjects than in MDS patients, although this difference was not significant (P ¼ 0.71). FLIP L levels in CD34 þ cells were negatively correlated with apoptosis in both normal and MDS marrows (P ¼ 0.03). FLIP Short RNA expression was higher in MDS patients than in normal controls in both BMMNC (P ¼ 0.03) and CD34 þ cells (P ¼ 0.08). In contrast to FLIP L , FLIP St levels were positively correlated with apoptosis. At the protein level FLIP was most readily detectable in patients with high blast counts. The data suggest that FLIP L and FLIP S are differentially regulated, and that the relative levels of both isoforms play a role in the regulation of apoptosis in MDS.
Introduction
Apoptosis is a physiologic process, critical for the control of cell proliferation and removal of supernumerary, abnormal and senescent cells. 1 However, under pathological conditions, for example, in patients with a myelodysplastic syndrome (MDS), apoptosis is dysregulated. [2] [3] [4] [5] [6] Several apoptosis-inducing ligand/ receptor pathways have been identified 1, [7] [8] [9] and have been shown to be upregulated in MDS marrow. 4, [10] [11] [12] [13] FAS ligand (FAS-L) and tumor necrosis factor-alpha (TNF-a) induce apoptosis by binding to their natural receptors FAS (CD95/Apo-1) and TNF receptors 1 (TNFR1) and 2 (TNFR2), respectively. 7, 8 The TNF-related apoptosis-inducing ligand (TRAIL) also initiates apoptosis through binding to death receptors DR4 (TRAIL receptor 1) and DR5 (TRAIL receptor 2); however, nonagonistic (decoy) receptors (TRAIL receptors 3 and 4) compete for TRAIL binding. 7, 9 We have previously shown that the ratio of agonistic to decoy receptors in MDS marrow is upregulated in comparison to marrow from normal donors. 13 Such a pattern would favor the occurrence of apoptosis in MDS cells relative to normal marrow cells. However, in MDS marrow, apoptosis occurs in normal as well as in clonal precursors. 13 While this may be due to signals transmitted via other death receptors, it is also possible that death signals are modulated differentially in normal and transformed (clonal) hemopoietic precursors. 13 Binding of TRAIL and FAS-L to the respective death receptors activates a common intracellular death signaling pathway, that is, formation of the death-inducing signaling complex (DISC), which results in the activation of caspase-8. 7, 9, 14 This step links the death receptor to downstream signal transduction and leads to the activation of a cascade of other caspases, the key effector molecules of apoptosis. 7, 14, 15 Both FAS-L-and TRAIL-mediated intracellular signals can be blocked by the caspase inhibitory protein FLIP (FLICE (FAS-associated death-domain-like IL-1-converting enzyme) inhibitory proteins)), of which at least four splice variants have been identified. 14, [16] [17] [18] [19] The largest variant FLIP Long (FLIP L ), a protein of 440 amino acids is highly homologous to caspase-8. 14 In fact, FLIP L contains a caspaselike domain at the carboxy-terminus but, as indicated by the name, was originally characterized as a molecule with inhibitory activity on caspase-8. 14 The short splice form termed FLIP Short (FLIP S ) contains 202 amino acids and has also been characterized as a potent inhibitor of (TRAIL-induced) apoptosis. 14, 16 However, while both FLIP L and FLIP S have been described as inhibitors of death receptor pathways, [16] [17] [18] [19] recent data suggest that FLIP L , at physiologic levels, may in fact have caspase-8-activating properties. 20 The aim of the present study was to characterize the expression of FLIP L and FLIP S at the mRNA and protein levels in marrow cells and to correlate the expression levels with apoptosis as assessed by flow cytometry. We hypothesized that FLIP expression differed between normal and MDS marrows, and that high levels of FLIP L , FLIP S or both would have an impact on the rate of apoptosis in MDS marrow.
Materials and methods

Marrow samples and cell lines
Marrow aspirates were obtained from 17 healthy volunteer donors (seven males, 10 females; 25-55 (median 39) years of age) and 29 patients with MDS. All marrow donors had given informed consent using procedures approved by the Institutional Review Board of the Fred Hutchinson Cancer Research Center (FHCRC). Clinical characteristics of patients with MDS are shown in Table 1 . The majority of patients (N ¼ 19) had lessadvanced MDS (o5% marrow blasts). Two patients were classified as having refractory anemia with excess of blasts (RAEBs; 10 and 14% marrow blasts, respectively), three patients as having RAEB in transformation (RAEB-T; 20-30% marrow blasts), two had evolved into AML (430% blasts) and three had CMML (with less than 5% blasts), respectively. In addition, CD34 þ selected peripheral blood stem cells (PBSCs) from normal individuals obtained after mobilization (N ¼ 8), and eight human cell lines (stroma cell line HS5, promyelocytic leukemia cell line HL60, lymphoblastoid T-cell line JURKAT, erythroleukemia cell line K562, myeloblastic cell lines KG1a and ML1, monocytic cell line U937 and MDS cell line MUTZ- 1 21 ) were analyzed.
Preparation of cells
Bone marrow mononuclear cells (BMMNCs) were isolated by Ficoll-Hypaque density-gradient centrifugation. After red blood cell lysis with ammonium chloride-containing buffer, cells were resuspended and washed twice in phosphate-buffered saline (PBS). BMMNC aliquots were either used for flow cytometry or treated with modified RIPA buffer (150 mM NaCl, 1% Triton X, 0.1% sodium dodecyl sulfate (SDS), 0.5% Nadeoxycholate, 50 mM Tris-HCl, pH 8.0) containing 100 ml protease inhibitor complex (Complete, Mini; Roche, Mannheim, Germany) and 5 ml 0.5 mM phenylmethylsulfonylfluoride to obtain a protein lysate for Western immunoblotting. Alternatively, cells were lysed in RLT buffer containing b-mercaptoethanol for RNA extraction. 
Antibodies for flow cytometry
Immunomagnetic cell separation
In 20 patients with MDS and 11 healthy volunteers marrow aspirates yielded sufficient numbers of cells (absolute minimum: 1 Â 10 7 BMMNC) for magnetic-activated cell sorting (MACS). MACS was carried out using the Direct CD34 Progenitor Cell Isolation Kit (Miltenyi Biotech, Bergisch-Gladbach, Germany) according to the manufacturer's recommendations. Briefly, cells were resuspended in Miltenyi buffer (1 Â PBS with EDTA supplemented with 0.5% human serum) in a final volume of 300 ml/10 8 cells and incubated with 100 ml CD34 microbeads (per 10 8 cells) and 100 ml blocking reagent (per 10 8 cells) at 41C for 30 min. After washing and resuspending in 2 ml of Miltenyi buffer, a double-positive CD34 separation (to increase purity) was performed on an autoMACS (Miltenyi Biotech). Viability of CD34 þ cells was assessed after separation using the trypan blue dye exclusion assay and was 490%.
Western immunoblotting
The protein concentration of cell lysates (BMMNC as well as CD34 þ cells) was determined using the Bio-Rad (Hercules, CA, USA) protein assay. In total, 20-30 mg of each lysate was loaded on 4-20% SDS-polyacrylamide gels, electropheresed at 120 V for 1-1.5 h using a Mini Trans-Blot s Electrophoretic Transfer Cell (Bio-Rad) under reducing conditions and then transferred onto PVDF membranes. After transfer, the PVDF membranes were blocked for 1 h in PBS-T (PBS with 0.25% Tween-20) containing 2% nonfat dry milk and then incubated with mouse polyclonal primary anti-FLIP antibody (NF6; a kind gift from Dr P Krammer, Deutsches Krebsforschungszentrum, Heidelberg, Germany) diluted 1:500 in blocking solution overnight at 41C. After repeated washings in PBS-T, the blot was probed with a secondary antibody (diluted 1:10 000-20 000 in blocking solution) coupled to horseradish peroxidase for 1 h at room temperature and developed using an enhanced chemiluminescence detection kit (Pierce, Rockford, IL, USA).
RT-PCR
Total RNA was isolated from BMMNC or CD34 þ cells using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA) after sample homogenization with the QIAshreddert column (Qiagen). Concentration and purity of RNA were determined by measuring absorbance spectrophotometrically at A260/A280. cDNA was then synthesized using the SuperScriptTM II RNAse H À Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. Briefly, 300-500 ng RNA, 1 ml Oligo(dT) 12À18 , 1 ml 10 mM dNTP and 10 ml DEPC water were heated at 651C for 5 min. After cooling on ice and centrifugation, 4 ml 5 Â first-strand buffer, 2 ml 0.1 M DTT and 1 ml RNAse inhibitor were added and incubated at 421C for 2 min. After the addition of 1 ml SuperScriptt II, the mixture was incubated for 50 min at 421C. Finally, the reaction was inactivated by heating to 701C for 15 min.
Cloning of FLIP L and FLIP S
Cloning of FLIP L and FLIP S cDNA into a pcDNA 3.1 plasmid was performed using the Directional TOPO Expression kit (Invitrogen) according to the manufacturer's protocol. The following primers were used: FLIP L and FLIP S forward primer, 5 0 -CAC CAT GTC TGC TGA AGT CAT C-3 0 ; FLIP L reverse primer, 5 0 -TTA TGT GTA GGA GAG GAT AAG TTT-3 0 ; FLIP S reverse primer, 5 0 -TCA CAT GGA ACA ATT TCC AAG AAT-3 0 .
Taqman PCR
The primers were chosen to hybridize to sequences in different exons to avoid amplification of genomic DNA. Probes labeled with 6-carboxy-fluorescein phosphoramidite at the 5 0 end and with 6-carboxy-tetramethyl-rhodamine as quencher at the 3 0 . Equal amounts of c-DNA were added into a PCR reaction mix containing 25 ml 2Â TaqMan s Universal PCR Master Mix (Applied Biosystems, Foster City, CA, USA), 12 ml DEPC water, 5 ml of 300 nM forward and reverse primers and 1 ml of probe (stock 10 mM) in a total volume of 50 ml. All samples were analyzed in duplicates. VIC-labeled b-2 microglobulin was used as a house-keeping gene (internal positive control) and was purchased as a kit (Applied Biosystems). The reactions were performed in separate wells. The numbers of the FLIP L and FLIP S transcripts were determined by comparing the values with calibration curves obtained by serial dilution of plasmids (pcDNA 3.1) containing the full-length cDNA of each gene (see Figure 3) . All real-time quantitative PCR reactions were performed on an ABI Prism 7700 Sequence Detection System (Applied Biosystems) that captured the fluorescent signal and generated a real-time amplification plot. Thermal cycling conditions comprised an initial UNG incubation at 501C at 2 min, AmpliTaq Gold activation at 951C for 10 min, 40 cycles of denaturation at 951C for 15 s, and annealing and extension at 601C for 1 min.
For each sample, results were first calculated as a ratio of the total transcript number of FLIP L or FLIP S and the total transcript number of the endogenous reference gene (b-2 microglobulin) to obtain a normalized target value. To control for intertest variability equal amounts of c-DNA of the leukemic cell line KG1a known to express high amounts of FLIP L and FLIP S were analyzed with each quantitative PCR. Transcript ratios of each sample were normalized against the respective ratio of the KG1a cell line, and the ratio between the two was used as measure for the relative level of FLIP L (FLIP S ):
Statistical analysis
Summary statistics, such as median, range, mean and standard deviation (s.d.) were calculated for all flow cytometry and FLIP expression outcomes. Comparisons of flow cytometry and FLIP expression outcomes between normals and patients with MDS were carried out using a Wilcoxon rank-sum test. Pearson's correlation coefficients (r) between pairs of flow cytometry and FLIP expression outcomes were calculated on log-transformed versions of the variables. P-values for correlation coefficients are for a test of the null hypothesis that the correlation was zero. All reported P-values are two sided.
Results
Immunophenotypic analysis
Flow cytometric data are summarized in . No significant differences in CD95 expression were observed on CD14 þ , CD3 þ , or CD19 þ cells between patients with MDS and normal controls. The proportion of apoptotic BMMNC cells was higher in MDS marrow (29714%) than in normal marrow (21711%); however, there was considerable overlap, presumably related to the fact that in MDS marrow CD34 þ cells are composed of both clonal and normal precursors.
Western immunoblotting
We first determined FLIP expression in human cell lines and CD34 þ selected PBSC from normal individuals: all cell lines expressed FLIP L protein, with the strongest signal observed in KG1a (Figure 1a-g ). FLIP S was detectable only in KG1a (not shown). All CD34 þ PBSC samples also expressed high levels of FLIP L protein (Figure 1b) . In BMMNC of patients with MDS and normal individuals expression levels of FLIP L , as suggested by our initial data, 13 varied widely, and strong bands were detectable only in a small number of samples (Figure 1cand  d) . Both BMMNC and CD34 þ cell lysates from normal and MDS marrow showed FLIP L (55 kDa), but only very faint FLIP S (25 kDa) bands. BMMNC of four patients with a high proportion of marrow blasts showed the strongest FLIP L bands, suggesting that the level of FLIP L expression was correlated with blast content (Figure 1e-g ).
Highly purified samples of marrow CD34 þ cells for immunoblotting were available from nine patients. While in two patients with RAEB strong signals for FLIP L were detectable, in the remaining seven patients, with CMML (N ¼ 3), RA (N ¼ 3) or RARS (N ¼ 1), none or only weak bands were present ( Figure  1f and g ). These results further support the concept that FLIP L was expressed predominantly in myeloblasts and probably upregulated with disease progression. As the CD34 þ blast population tends to expand with disease progression, and the rate of apoptosis declines, 22, 23 the expression of FLIP L in CD34 þ precursors is also consistent with this model.
Quantitative FLIP L and FLIP S expression
In an attempt to further characterize the expression of FLIP, we carried out real-time quantitative PCR. We expressed FLIP RNA levels as ratios relative to a standard, as described under Materials and methods. Results are summarized in Table 3 and Figures 2 and 3 . In BMMNC, the median FLIP L level was 2.13 (range 0.55-4.13) for normal individuals and 1.67 (range 0.46-6.94) for patients with MDS, respectively (Figure 2a) . The difference was not statistically significant. Conversely, FLIP S levels in BMMNC from normal controls were significantly lower (median 0.25, range 0.2-0.9) than in patients with MDS (median 0.47, range 0.14-16.26) (P ¼ 0.03) (Figure 2b) .
In CD34 þ cells, the median FLIP L level was 1.3 (range 0.39-6.63) in normal individuals and 0.76 (range 0.34-1.64) in patients with MDS (P ¼ 0.04) (Figure 3a) . Conversely, the median relative FLIP S level in CD34 þ cells in normal controls was lower (median 0.32, range 0.1-0.59) than in patients with MDS (median 0.47, range 0.1-2.31) (P ¼ 0.08) (Figure 3b ). These differences in the quantitative ratio between FLIP L and FLIP S in normal marrow as compared to MDS marrow suggest differential regulation of the two FLIP forms. It is important to note that cells from all MDS marrows (BMMNC and CD34 þ cells) were composed of clonal and normal cells. Thus, any result derived from clonal precursors is likely to be 'diluted' by the contributions of normal cells.
Correlation between FLIP expression and apoptosis in CD34 þ cells
Among normal subjects there was a statistically significant negative correlation for both FLIP L and FLIP S with apoptosis in CD34 þ cells as assessed by Annexin V staining (r ¼ À0.53, P ¼ 0.03 for FLIP L ; r ¼ À0.53, P ¼ 0.04 for FLIP S , respectively). In CD34 þ cells from patients with MDS, a negative correlation was observed only for FLIP L (r ¼ À0.42, P ¼ 0.06), while, in contrast, the expression of FLIP S was positively correlated with apoptosis (r ¼ 0.5, P ¼ 0.03). Those correlations, together with the lower FLIP L and higher FLIP S levels in MDS marrow (with higher rates of apoptosis) compared to normal marrow suggest that both splice variants are involved in the regulation of apoptosis. A higher rate of apoptosis in MDS marrow could be related to lower levels of FLIP L . The role of higher levels of FLIP S is more difficult to explain. The possibility of an interrelationship between decreasing levels of the FLIP L splice variant and rising levels of FLIP S must be considered. While documentation of a strict correlation between protein and RNA levels in patient samples proved difficult because of very low levels of protein in many samples, the correlation of RNA levels with apoptosis strongly supports the relevance of FLIP for apoptosis. Also, there was a clear correlation between RNA and protein levels in cell lines KG1a and ML-1.
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Discussion
Apoptosis has been shown to be involved in the pathophysiology of MDS. [3] [4] [5] [6] 25 The process of apoptosis is complex and highly regulated by pro-and antiapoptotic signals. We and others have shown upregulation of apoptosis-inducing systems at the ligand (TNF-a, IL-1b, TRAIL, FAS-L) and receptor levels (FAS, TRAIL receptors) in patients with MDS.
4,10-13 Raza et al. showed in creased activity of both caspase-1 and -3 in short-term marrow cultures of patients with MDS. 26, 27 Bouscary et al 28 found higher levels of active caspase-3 in early stages of MDS than in normal controls.
The role of FLIP, a cytoplasmic protein that modulates TRAILand FAS-mediated signals 14, [16] [17] [18] [19] [20] 29, 30 has not yet been characterized in MDS. We proposed recently that the ratio of agonistic and decoy receptors for TRAIL on MDS marrow cells was a determinant of the extent of apoptosis that occurred. 13 However, TRAIL-initiated signals are also modulated at the cytoplasmatic level by various adaptor molecules, including FLIP. The aim of the present study was, therefore, to characterize the expression of FLIP L and FLIP S in hemopoietic cells. FLIP expression at the protein level varied from cell line to cell line, and was variable in normal and MDS marrows: in BMMNC from MDS marrows, high FLIP L levels were detectable only in patients with high marrow blast counts, whereas in most normal and MDS marrows with low blast counts weak or no signals were detected. In CD34 þ cells, the highest levels of FLIP L protein were present in two patients with RAEB. The same two patients also had high FLIP L RNA levels in Taqman-PCR (1.35 and 1.63, respectively; median of all samples studied: 0.76). In patients with very low blast counts, clear correlations between FLIP RNA and protein levels were not established due to very low protein levels. Second, we confirmed the hypothesis of significantly lower FLIP L levels in BMMNC and CD34 þ cells in patients with MDS than in normal controls. However, third, both normal and MDS marrows showed an inverse correlation between FLIP L expression and CD34 þ cell apoptosis as assessed by Annexin V staining. These data also confirm and expand the report by Kim et al, 29 who showed high levels of FLIP L expression in normal CD34 þ cells obtained from peripheral blood. In addition, we showed that in MDS marrow FLIP S levels in BMMNC and CD34 þ cells were higher than in normal controls. Interestingly, the level of expression of FLIP S in CD34 þ cells was positively correlated with CD34 þ cell apoptosis in MDS marrow. The mechanism by which FLIP S levels would modify apoptosis is not immediately apparent. It is generally accepted that FLIP S does not activate the first cleavage step of caspase-8 30, 31 and, in fact, may act as an inhibitor of FLIP L with respect to caspase-8 activation and induction of apoptosis. DISC-associated caspase-8 activity correlates inversely with FLIP S concentration, 32 suggesting that the rate of apoptosis should be decreased with high FLIP S levels. Although those studies were mostly conducted in lymphoid cells and should be extrapolated with caution, they raise questions about a positive correlation of FLIP S levels and apoptosis. One can speculate that increasing FLIP S levels resulted from dysregulation associated with declining levels of FLIP L , and low FLIP L levels have indeed been shown to facilitate caspase-8 activation. 20, 30, 33 There are several recent reports that suggest that FLIP L and FLIP S expressions are differentially regulated. Micheau et al 33 showed that FLIP is under the control of the nuclear transcription factor (NF)-kB, and that both FLIP L and FLIP S are upregulated by signals leading to NF-kB activation (eg TNFa). However, dependent on the cells studied, induction by TNF-a followed differential kinetics. This was confirmed by other investigators, 34 who showed that FLIP L was induced by the mitogen-activated protein kinase (MAPK) ERK, where as FLIP S was induced by the MAPK JNK. 35 Studies in rat granulosa cells and human ovarian cancer cell lines have shown that TNF-a selectively upregulates FLIP S (but not FLIP L ). 35, 36 As TNF-a is upregulated in many patients with MDS, it is conceivable that this also results in increased levels of FLIP S .
The lower FLIP L level in MDS marrows, in addition to the well described upregulation of extracellular proapoptotic signals, including TNF-a, in MDS, would explain the increased susceptibility of hemopoietic cells in MDS marrow to deathinducing stimuli. Differential regulation of FLIP L and FLIP S , and different ratios of the two splice variants in various cell populations, might result in different rates of apoptosis. Further studies are needed to elucidate the mechanisms controlling and regulating FLIP expression in normal and malignant hemopoietic cells.
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